BridgeBio Pharma, Inc. Operating Expenses
BridgeBio Pharma, Inc. (BBIO) reported Operating Expenses of $167.97 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2021-05-06
- BridgeBio Pharma, Inc. operating expenses for the quarter ending 2021-03-31 was $167.97M, a 63.89% increase year-over-year.
- BridgeBio Pharma, Inc. operating expenses for the quarter ending 2020-12-31 was $127.61M, a 38.02% increase year-over-year.
- BridgeBio Pharma, Inc. operating expenses for the quarter ending 2020-09-30 was $128.07M, a 57.58% increase year-over-year.
- BridgeBio Pharma, Inc. operating expenses for the quarter ending 2020-06-30 was $124.57M, a 79.70% increase year-over-year.
- BridgeBio Pharma, Inc. operating expenses for fiscal 2020 was $482.73M, a 57.34% increase from fiscal 2019.
- BridgeBio Pharma, Inc. operating expenses for fiscal 2019 was $306.80M, a 67.05% increase from fiscal 2018.
- BridgeBio Pharma, Inc. operating expenses for fiscal 2018 was $183.66M, a 318.76% increase from fiscal 2017.
- BridgeBio Pharma, Inc. operating expenses for fiscal 2017 was $43.86M.
| Period end | Operating Expenses 1 month | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | $167.97M 10-Q · filed 2021-05-06 | $295.58M derived: sum of 2 quarters · filed 2021-05-06 | $423.64M derived: sum of 3 quarters · filed 2021-05-06 | $548.21M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2020-12-31 | $127.61M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $255.68M derived: sum of 2 quarters · filed 2021-02-25 | $380.24M derived: sum of 3 quarters · filed 2021-02-25 | $482.73M 10-K · filed 2021-02-25 | |
| 2020-09-30 | $128.07M 10-Q · filed 2020-11-05 | $252.63M derived: sum of 2 quarters · filed 2020-11-05 | $355.12M 10-Q · filed 2020-11-05 | $447.58M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2020-06-30 | $124.57M 10-Q · filed 2020-08-11 | $227.05M 10-Q · filed 2020-08-11 | $319.51M derived: sum of 3 quarters · filed 2021-05-06 | $400.78M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2020-03-31 | $102.49M 10-Q · filed 2021-05-06 | $194.94M derived: sum of 2 quarters · filed 2021-05-06 | $276.22M derived: sum of 3 quarters · filed 2021-05-06 | $345.54M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | $92.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $173.73M derived: sum of 2 quarters · filed 2021-02-25 | $243.05M derived: sum of 3 quarters · filed 2021-02-25 | $306.80M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $81.27M 10-Q · filed 2020-11-05 | $150.59M derived: sum of 2 quarters · filed 2020-11-05 | $214.34M 10-Q · filed 2020-11-05 | $279.93M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $69.00K 10-Q · filed 2019-08-14 | $69.32M 10-Q · filed 2020-08-11 | $133.07M 10-Q · filed 2020-08-11 | $198.65M derived: sum of 3 quarters · filed 2021-02-25 | $240.11M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $63.75M 10-Q · filed 2020-05-14 | $129.34M derived: sum of 2 quarters · filed 2021-02-25 | $170.79M derived: sum of 3 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $65.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $107.04M derived: sum of 2 quarters · filed 2021-02-25 | $183.66M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $41.46M 10-Q · filed 2019-11-08 | $118.08M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | $43.86M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |